Is BioAffinity Technologies Stock a Good Investment?
BioAffinity Technologies Investment Advice | BIAFW |
Not Rated
Examine BioAffinity Technologies Stock
Researching BioAffinity Technologies' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if BioAffinity Technologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioAffinity Technologies' research are outlined below:
| BioAffinity Technologies is not yet fully synchronised with the market data | |
| BioAffinity Technologies is way too risky over 90 days horizon | |
| BioAffinity Technologies has some characteristics of a very speculative penny stock | |
| BioAffinity Technologies appears to be risky and price may revert if volatility continues | |
| BioAffinity Technologies has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies Warrant has accumulated 1.5 M in total debt. BioAffinity Technologies has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about BioAffinity Technologies' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the revenue of 9.36 M. Net Loss for the year was (9.04 M) with profit before overhead, payroll, taxes, and interest of 3.03 M. | |
| bioAffinity Technologies Warrant has accumulated about 214.4 K in cash with (7.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Latest headline from businesswire.com: bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference |
BioAffinity Technologies Quarterly Cost Of Revenue |
|
BioAffinity Technologies' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.09) | (2.19) | |
| Return On Capital Employed | (2.63) | (2.50) | |
| Return On Assets | (1.39) | (1.46) | |
| Return On Equity | (3.47) | (3.30) |
Determining BioAffinity Technologies' profitability involves analyzing its financial statements and using various financial metrics to determine if BioAffinity Technologies is a good buy. For example, gross profit margin measures BioAffinity Technologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioAffinity Technologies' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in BioAffinity Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of bioAffinity Technologies Warrant. Check BioAffinity Technologies' Beneish M Score to see the likelihood of BioAffinity Technologies' management manipulating its earnings.
Evaluate BioAffinity Technologies' management efficiency
The company has return on total asset (ROA) of (0.8858) % which means that it has lost $0.8858 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.9085) %, meaning that it generated substantial loss on money invested by shareholders. BioAffinity Technologies' management efficiency ratios could be used to measure how well BioAffinity Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.19 in 2025. Return On Capital Employed is likely to climb to -2.5 in 2025. At this time, BioAffinity Technologies' Non Current Assets Total are fairly stable compared to the past year. Total Current Assets is likely to climb to about 3.8 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 15.1 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.21 | 0.23 | |
| Tangible Book Value Per Share | 0.03 | 0.04 | |
| Enterprise Value Over EBITDA | (1.37) | (1.44) | |
| Price Book Value Ratio | 4.24 | 4.45 | |
| Enterprise Value Multiple | (1.37) | (1.44) | |
| Price Fair Value | 4.24 | 4.45 | |
| Enterprise Value | 13.4 M | 12.7 M |
The strategic decisions made by BioAffinity Technologies management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Beta 2.557 |
BioAffinity Technologies' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioAffinity Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioAffinity Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioAffinity Technologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand BioAffinity Technologies' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing BioAffinity Technologies' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0197 | |||
| Market Risk Adjusted Performance | 0.23 | |||
| Mean Deviation | 11.46 | |||
| Semi Deviation | 11.77 | |||
| Downside Deviation | 16.21 | |||
| Coefficient Of Variation | 9241.65 | |||
| Standard Deviation | 22.7 | |||
| Variance | 515.33 | |||
| Information Ratio | 0.0046 | |||
| Jensen Alpha | 0.0955 | |||
| Total Risk Alpha | (2.94) | |||
| Sortino Ratio | 0.0065 | |||
| Treynor Ratio | 0.22 | |||
| Maximum Drawdown | 165.91 | |||
| Value At Risk | (26.09) | |||
| Potential Upside | 46.15 | |||
| Downside Variance | 262.82 | |||
| Semi Variance | 138.6 | |||
| Expected Short fall | (31.75) | |||
| Skewness | 3.04 | |||
| Kurtosis | 14.3 |
| Risk Adjusted Performance | 0.0197 | |||
| Market Risk Adjusted Performance | 0.23 | |||
| Mean Deviation | 11.46 | |||
| Semi Deviation | 11.77 | |||
| Downside Deviation | 16.21 | |||
| Coefficient Of Variation | 9241.65 | |||
| Standard Deviation | 22.7 | |||
| Variance | 515.33 | |||
| Information Ratio | 0.0046 | |||
| Jensen Alpha | 0.0955 | |||
| Total Risk Alpha | (2.94) | |||
| Sortino Ratio | 0.0065 | |||
| Treynor Ratio | 0.22 | |||
| Maximum Drawdown | 165.91 | |||
| Value At Risk | (26.09) | |||
| Potential Upside | 46.15 | |||
| Downside Variance | 262.82 | |||
| Semi Variance | 138.6 | |||
| Expected Short fall | (31.75) | |||
| Skewness | 3.04 | |||
| Kurtosis | 14.3 |
Consider BioAffinity Technologies' intraday indicators
BioAffinity Technologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioAffinity Technologies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.89 | |||
| Day Median Price | 0.16 | |||
| Day Typical Price | 0.16 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.02) | |||
| Relative Strength Index | 43.68 |
BioAffinity Stock media impact
There is far too much social signal, news, headlines, and media speculation about BioAffinity Technologies that are available to investors today. This information is accessible both publicly - through BioAffinity Technologies' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of BioAffinity-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of BioAffinity Technologies news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioAffinity Technologies relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioAffinity Technologies' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioAffinity Technologies alpha.
BioAffinity Technologies Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards BioAffinity Technologies can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioAffinity Technologies Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioAffinity Technologies stock to make a market-neutral strategy. Peer analysis of BioAffinity Technologies could also be used in its relative valuation, which is a method of valuing BioAffinity Technologies by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
BioAffinity Technologies Corporate Management
| Dallas Coleman | National Sales | Profile | |
| William Bauta | Senior Therapeutics | Profile | |
| Maria JD | President, Founder | Profile | |
| Gordon MD | Chief Officer | Profile | |
| Xavier MS | VP Operations | Profile |
Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.